Member Info for Luckenbach

Thanks Westernglory, below some figures with a disclaimer. Only playing with artificial assumptions here to make it easy and surely not correct.

Celgene’s revenue in 2018 was 15,3b. So with 50000 $ average (fictive) per patient it would mean 300000 patients. It had over 8800 employees. It was bought with 74b$ by BMS in 2019.

Seagen’s revenue in 2022 was 2b. So with 50000$ average (fictive) per patient it would mean 40 000 patients. It had 3200 employees. It was agreed to buy with 43b$ by Pfizer last week.

Of course figures calculated as a proportion of revenues can’t be compared as such because of the different business and partnering models. The total value of their inventions on the market can’t be judged with these figures. The agreed acquisition prices are only a part of the inventions total value on the market. The financial value the partners are gaining is not included.

Celgene’s
Revenue/employee 1,73m$
Valuation/employee 8,4m$
Net income/employee 0,45m$
Seagen’s
Revenue/employee 0,63m$
Valuation/employee 13,4m$
Net income/employee -190$ (negative)

Faron’s Mcap per employee is 4m$. It will be a journey to transform from a novel status up to an established position in the market. From the figures above we can see that in Seagen’s price there is much more future value calculated in compared to Celgene?

Does anybody know how many cancer patients have been treated with Celgene’s and Seagen’s therapies? What is the annual level in amount of patients and future potential of their drugs in program?

…who knows?

Ok, have to add one option more
h) hell of a lot
But have to say those in that category are usually more established companies than novel ones? Who konesalisi? tell me what is humongous? At least it would help hundreds of thousands patients?

"I am looking forward to joining the Board of Faron at this exciting time," said Mr Pätsi. "Bexmarilimab with its innovative mechanism of action and clinical data so far holds great promise in multiple cancer indications where better treatments are desperately needed."

Would be nice to know how he sees the potential of Bex and the potential future value of the company:
a) zero
b) 200m like today
c) 350m
d) 2b
e) 5b
f) 7-12b
g) more

Keytruda patent ends in the US in 2028 and in EU in 2030. They’ve and some other PDs have done a good money and they certainly should be encouraged to pay for a deal with Bex because 87% of the patients still not getting benefit.

I don’t know what all it means when Keytruda or other PD patents ends. Any generic programs on their way already or not? Maybe too much asked to try to substitute one? Maybe not if PD-1s’ are not that different from each other.

Does it matter running out of patents if the whole PD-1 market will be priced like kind of a generic way right after the first one is substituted with low prices? Maybe not that simple for the reason that these eight PDs’ have approvals for various cancers?

So was it the first one or the last one that should be the licensing target? Should FDA recommend every PD-1 to get into the next phase with Bex for the sake that a reasonable part of those 87% of the patients could get help together with Bex? Results are encouraging now and bigger resources could make a big difference together with existing drugs. Every PD could have a chance and it would be equal opportunity for all to participate accelerated approval process with Bex. Maybe a bit idealistic but could be in line with the FDA’s call that do not develop more CPIs but completing drugs. Of course BPs would like to have their own bex-like drugs instead of Bex?

But first the Bexmab approval.

I quess scientists discussing there.

Activity on the Finnish Board. Would be nice to inherit some here too and visa versa.

Very strong! They have the codes to open the locks. Only a question of which of those opens first as a result of optimizing input and output within a meaningful timeframe. I like the word humongous! Number seven got a new meaning and as we know seven is not symbolizing humongous in any scale.

Thanks Sax. That is what’s needed, awareness and credibility through scientific research and publications presented in scientific forums and media. Very good indeed. Thanks to those scientist’s the therapeutic potential of Bex is validated in AML and MDS (ex vivo). Of course the company itself has been orienting and acting with this knowledge for some time and advancing in clinical trials as we know. This should rise the interest of Bex on Clever-1 in blood cancers as well on solid tumors too among pharma industry.

On the 3 March they report 2022 results. Webcast and interviews promised says P. Koivisto Faron’s communication responsible on the Finnish Inders chat and published a link to participate https://faron.videosync.fi/2022-financial-statement

So the value of the company is seen mainly in the potential of Bex says the article. It shows the FARON Inderes target price in a table which was -12.7% below the SP this morning. That indicates that things will still take time? We all know the future is behind many “locks”. But what if the locks will start opening one at a time. What might be the trigger that makes calculations change into more holistic evaluations where the whole potential could be played in. In the meantime it’s very good to have publicity. It was a decent article but apparently no Faron people interviewed.

For some the low volatility may do a favor by not triggering any sells and thus having a nice position when something matures up. Anyway up to 7 we all have the same risk to lose in this share even though we have different expectations. Getting up to 7 would be a very good sign.

Yes Westy, aren’t we excited!

…only as a rhetorical question

Thanks Sax! “Biorhythm” going to interfere in a constructive way? 1+1+1=?! What is the value of the company if each of these three could alone have a clinical approval and if useful together to form a healing homeostasis?

Sorry: What I am thinking is that some information is pending.

Hi Itsall, like you see from Sax’s message they had a gathering. Every company needs such event once and a while and especially when they are growing and ramping up new offices like we all know.

What I am thinking is that we Hegel some information is pending. Don’t know what but feels like they don’t want to have any inadequate buzz now but only official information. Is there a specific reason for that? Or just a change of a communication policy?

Nice socks with tree stripes, almost like SoC Standard of care as a goal for all lines Bex, Traumakine and Hematokine. Seems like typical company development days for higher spirit and cooperation, everyone is equally important, we make the future together as a company. Not necessarily team building because it’s different. Btw the communication responsible person seems not holding socks meaning no special message to me. Not meaning something could happen - maybe Dd undergoing and the while company stick together. LOL

…”relativity happiness” I would say and not even lost my money in real.